Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus
Open Access
- 2 February 2021
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine Case Reports
- Vol. 32, 101361
- https://doi.org/10.1016/j.rmcr.2021.101361
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Drug-Induced Sarcoidosis-Like ReactionsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2018
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsEuropean Respiratory Journal, 2017
- Balancing Immune Protection and Immune Pathology by CD8+ T-Cell Responses to Influenza InfectionFrontiers in Immunology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Highly Pathological Influenza A Virus Infection Is Associated with Augmented Expression of PD-1 by Functionally Compromised Virus-Specific CD8+T CellsJournal of Virology, 2014
- Viral acute lower respiratory infections impair CD8+ T cells through PD-1JCI Insight, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigensProceedings of the National Academy of Sciences of the United States of America, 2011
- High-resolution computed tomography findings from adult patients with Influenza A (H1N1) virus-associated pneumoniaEuropean Journal of Radiology, 2010
- Epidemiology and outcomes of serious influenza‐related infections in the cancer populationCancer, 2005